Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YIV-906 plus sorafenib vs placebo plus sorafenib in HBV-related advanced hepatocellular carcinoma
CTR20202692Phase 2Completed
- Sponsor
- Yiqi Medical
- Start
- Jan 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PHY906 in hepatocellular carcinoma (HCC), hepatitis B (HBV), sponsored by Yiqi Medical. Started Jan 2021; status: completed.
02
Drugs
PHY906
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on CTR20202692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202692.